Article Text

Download PDFPDF

Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response
  1. J Braun1,
  2. X Baraliakos1,
  3. J Listing2,
  4. C Fritz2,
  5. R Alten3,
  6. G Burmester4,
  7. A Krause5,
  8. S Schewe6,
  9. M Schneider7,
  10. H Sörensen8,
  11. H Zeidler9,
  12. J Sieper10
  1. 1
    Rheumatology Medical Center Ruhrgebiet, Herne
  2. 2
    German Rheumatism Research Center, Berlin
  3. 3
    Schlosspark Clinic, Berlin
  4. 4
    Charité Hospital, Humboldt University, Berlin
  5. 5
    Berlin-Buch Hospital, Berlin
  6. 6
    Ludwig-Maximilians-University, Munich
  7. 7
    Heinrich-Heine-University, Düsseldorf
  8. 8
    Immanuel Hospital, Berlin
  9. 9
    Medical University, Hannover
  10. 10
    University Medicine Berlin, Campus Benjamin Franklin, all Germany
  1. Prof.Dr. J Braun, Rheumazentrum Ruhrgebiet, Landgrafenstr. 15, 44652 Herne, Germany; j.braun{at}


Background: There is insufficient evidence for the long-term efficacy and safety of anti-tumour necrosis factor therapy in patients with ankylosing spondylitis (AS). This is the first report on the treatment with infliximab over 5 years.

Methods: As part of a multicentre randomised trial, 69 patients with active AS at baseline (BL) have been continuously treated with infliximab (5 mg/kg i.v. every 6 weeks)—except for a short discontinuation after 3 years (FU1). The primary outcome of this extension was remission according to the ASsessment in Ankylosing Spondylitis (ASAS) criteria at the end of year 5 of the study (FU2).

Results: Of the 43 patients who completed year 3, 42 agreed to continue, 38 of which (90.5%) finished year 5 (55% of 69 initially). Partial clinical remission was achieved in 13 of 38 patients (34.2%) at FU1 and FU2. At FU2, the mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was 2.5±1.9 (BL:6.4, FU1:2.5). BASDAI values <4 were seen in 79% of patients at both, FU1 and FU2. ASAS 20% and 40% responses were seen in 32 (84%) and 24 (63%) patients at FU2, respectively. Most patients classified as non-responders at FU2 were part-time responders, as all but one patient achieved an ASAS 20% response at least once within the last 2 years. Three types of responders were identified. No major side effects occurred during years 4 and 5 of infliximab therapy.

Conclusions: Infliximab is safe and efficacious in AS patients over 5 years. The majority of the patients remained on treatment and had rather persistent levels of low disease activity. Different response types could be identified.

View Full Text

Statistics from


  • Competing interests: Professors Braun and Sieper have received honoraria and grants from Centocor, Schering-Plough, Wyeth, Amgen, and Abbott.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.